Prognostic significance of CD56 and CD7 in acute myeloid leukaemia and their outcome.
BACKGROUND
The expression of CD7 and CD56 in Acute Myeloid Leukaemia was considered to be a poor prognostic factor for overall survival, complete remission but the result were limited and more prognostic parameter need to study. The importance of validating new prognostic parameters in acute myeloid leukaemia was the reason to investigate the prognostic significance of CD7 and CD56.


MATERIAL AND METHODS
Study involving patients who had newly diagnosed AML. Imunophenotyping was carried out at diagnosis and after induction therapy also compared with molecular and cytogenetics studies. End points were the leukaemia free survival, relapse-free survival, and overall survival.


RESULT
All 87 patients that were included in the study were divided into 4 groups based on expression of CD56 and CD7 as Group 1 (CD7+, CD56+), group 2 (CD7-, CD56+), group 3 (CD7+, CD56-) and group 4 (CD7-, CD56-) and were compared clinically and immunophenotypically. The clinical parameters that were correlated were age, sex, LFS (leukaemia free survival), Overall survival (OS) and Relapse Free survival (RFS) and were followed up with MRD at day 30 along with Molecular abnormalities and cytogenetic karyotyping.


CONCLUSION
The study data suggest that prognostic significance of CD7 and CD56 expression in patients of acute myeloid leukaemia could be indicative of poor prognosis as it was also associated with the adverse prognostic parameter (Minimal Residual Disease, high risk, shorter overall survival).
['Rai|Sandeep|S|', 'Singh|Saroj|S|', 'Gupta|Ritu|R|']
Acute myeloid leukaemia overall survival leukaemia free survival relapse free survival minimal residual disease leukaemia-associated immunophenotypes